CorriXR Therapeutics
CorriXR Therapeutics is a pioneering oncology-focused biotherapeutics development company developing genetic medicines to transform the treatment of solid tumors. Our first-in-class approach disables the transcription factor NRF2, a master regulator that controls 200+ genes that create a pro-oncogenic tumor microenvironment (TME). It is the highly complex cell survival mechanisms enabled by the tumor microenvironment that makes solid tumors so challenging to treat (90% failure rate). Attempts to alter the TME with targeted approaches have largely failed due to the compensatory mechanisms that are triggered when cancer cells are under attack. By knocking out an upstream target, these compensatory mechanisms are overwhelmed, disrupting the cancer cell survival mechanisms and making them more sensitive to standard of care - we believe this is a critical success factor for the treatment of solid tumors.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}